|

The Revolution in Mental Health Care: Psychedelics | PSILERA

ByPsychedelic Spotlight



In today’s episode, we speak with the leaders of Psilera Bioscience, Chris Witowski and Jackie von Salm, who discuss the revolution in mental health care that psychedelics represent.

Psilera is a company focused on using chemistry to find the ideal psycho-active substance. They are also interested in the intersection between consciousness and psychedelics.

A couple of the questions Psilera hopes to answer are as follows:
1. Can psychedelics treat addiction?
2. Can psychedelics treat mood disorders?

In this fantastic conversation, while focusing on the science of psychedelics, the co-founders also dig deep into the philosophy of psychedelics. For example, can psychedelics be both medicines and recreational? And if they are medicinal, what are the differences between substances like psilocybin, LSD and DMT?

In the discussion, it is mentioned that it is important to not just treat the symptoms of trauma, but get at the root causes, which they believe psychedelics and psychedelic therapy can do.

Enjoy this great conversation!

Timestamps:

00:00- Intro + why are psychedelics as medicines appealing?
2:22- Consciousness and psychedelics
4:12- Can psychedelics treat addiction and Mood Disorders?
11:11 – Can Psychedelics be both medicine and used recreationally?
13:50- Our addiction culture and whether psychedelics can help

#PsileraBioscience #Psychedelics #PsychedelicMedicine

source

Similar Posts

  • Red Light Holland CANNABIS Merger, Atai IPO, NUMI Uplists, MindMed & More (TRUFF, atai, Numi, MMED)

    Listen, Videos

    LOTS of news happened this week, one of the major ones being Red Light Holland’s merger with a CANNABIS Company called Cresco. Other news we discuss in today’s segment is atai Life Sciences Nasdaq uplisting, MindMed’s new addition to the team, Numinus’ Uplisting and Field Trip’s upcoming financial results.

    Enjoy!

    Timestamps:

    0:00 – Intro
    1:00 – atai Life Sciences Nasdaq IPO
    2:56 -Red Light Holland Merging With A Cannabis Company & Acquisition
    7:26 -Numinus Wellness Uplists To The TSX
    8:45 – MindMed Appoints Peter Bergethon To Their Scientific Advisory Board
    10:36 – Field Trip’s Upcoming Financial Results

    Links:
    atai Life Sciences ( NASDAQ: atai)
    https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html

    Red Light Holland ( CSE: TRIP / OTC: TRUFF) Closes Acquisition of 80% of Happy Caps Mushroom Farm:
    https://ca.finance.yahoo.com/news/red-light-holland-closes-acquisition-122000805.html

    Red Light Holland is Merging with a Cannabis company called Creso Pharma to create The HighBrid Lab:
    https://www.newsfilecorp.com/release/87740/Creso-Pharma-and-Red-Light-Holland-Merge-to-Introduce-The-HighBrid-Lab-TM-a-Leading-Global-Psychedelics-x-Cannabis-Company-Specializing-in-Recreational-Products-Applied-Science-Technology-and-Innovation

    Numinus Wellness (OTC: LKYSF, TSX.V: NUMI) Uplists to Tier 1 on the TSX Venture Exchange:
    https://thecannabisstock.com/2021/06/18/numinus-wellness-gradu

    MindMed (NASDAQ: MNMD, NEO: MMED) Appoints Pharmaceutical Veteran, DR Peter Bergethon to their Scientific Advisory Board:
    https://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html

    Field Trip Health (OTC: FTRPF, TSX: FTRP) Will Release Financial Results for its fiscal fourth quarter and full year 2021 ended March 31, 2021:
    https://ca.movies.yahoo.com/field-trip-health-ltd-announces-131000469.html
    https://www.meetfieldtrip.com/news/news-details/2021/Field-Trip-Health-Ltd.-Schedules-Fiscal-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Conference-Call-for-Friday-June-25-2021-At-800-am-ET/default.aspx

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #RedLightHolland #MindMed #atai

  • Interview With Tesla La Touche

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we spend some time with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry. 

  • HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)

    Listen, Videos

    HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?

    Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
    In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.

    HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.

    Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.

    The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .

    https://havnlife.com/
    CSE: HAVN | OTC: HAVLF | FRA: 5NP

    #HAVN #HAVNLifeSciences #Mindmed